↓ Skip to main content

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Overview of attention for article published in Journal of Hematology & Oncology, February 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

patent
9 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
359 Dimensions

Readers on

mendeley
219 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Published in
Journal of Hematology & Oncology, February 2010
DOI 10.1186/1756-8722-3-5
Pubmed ID
Authors

Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo, Delong Liu

Abstract

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies. At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies. This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.

Mendeley readers

The data shown below were compiled from readership statistics for 219 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
Denmark 2 <1%
Brazil 1 <1%
Germany 1 <1%
Belgium 1 <1%
China 1 <1%
United States 1 <1%
Poland 1 <1%
Unknown 209 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 52 24%
Researcher 46 21%
Student > Master 29 13%
Student > Bachelor 18 8%
Other 13 6%
Other 42 19%
Unknown 19 9%
Readers by discipline Count As %
Agricultural and Biological Sciences 92 42%
Medicine and Dentistry 37 17%
Chemistry 24 11%
Biochemistry, Genetics and Molecular Biology 20 9%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Other 13 6%
Unknown 24 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2019.
All research outputs
#3,487,830
of 17,360,236 outputs
Outputs from Journal of Hematology & Oncology
#177
of 860 outputs
Outputs of similar age
#59,866
of 297,383 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 9 outputs
Altmetric has tracked 17,360,236 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 860 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,383 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.